Your session is about to expire
← Back to Search
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) (CIN-002 Trial)
Phase 1
Waitlist Available
Research Sponsored by Children's Hospital Medical Center, Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Summary
The purpose of this study is to determine a suitable dose of the human norovirus GII.4 challenge pool(CIN-1;031693) that induces illness in approximately 50% of susceptible subjects that would be useful for evaluation of vaccines and antivirals.
Eligible Conditions
- Norovirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose range evaluation of Norovirus challenge pool (GII.4, CIN-1)
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Norovirus challenge pool (GII.4, CIN-1)Experimental Treatment1 Intervention
Group II: Sterile waterPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Norovirus challenge pool (GII.4, CIN-1)
2011
Completed Phase 1
~60
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Children's Hospital Medical Center, CincinnatiLead Sponsor
839 Previous Clinical Trials
6,565,543 Total Patients Enrolled
LigoCyte Pharmaceuticals, Inc.Industry Sponsor
1 Previous Clinical Trials
61 Total Patients Enrolled
1 Trials studying Norovirus
61 Patients Enrolled for Norovirus